Discovery of Novel 2-Oxoacetamide Derivatives as B3GAT3 Inhibitors for the Treatment of Hepatocellular Carcinoma
Authors:
- 26 June 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (13) , 10743-10773
Abstract
Beta-1,3-glucuronosyltransferase (B3GAT3), overexpressed in hepatocellular carcinoma (HCC) and negatively correlated to prognosis, is a promising target for cancer therapy. Currently, no studies have reported small molecule inhibitors of B3GAT3. In this study, we designed and synthesized a series of small-molecule inhibitors of B3GAT3 through virtual screening and structure optimization. The lead compound TMLB-C16 exhibited potent B3GAT3 inhibitory activity (KD = 3.962 mu M) by effectively suppressing proliferation and migration, and inducing cell cycle arrest and apoptosis in MHCC-97H (IC50= 6.53 +/- 0.18 mu M) and HCCLM3 (IC50= 6.22 +/- 0.23 mu M) cells. Furthermore, compound TMLB-C16 demonstrated favorable pharmacokinetic properties with a relatively high bioavailability of 68.37%. It significantly inhibited tumor growth in both MHCC-97H and HCCLM3 xenograft tumor models without causing obvious toxicity. These results indicate that compound TMLB-C16 is an effective small molecule inhibitor of B3GAT3, providing a basis for the future development of B3GAT3-targeted drugs.Keywords
Funding Information
- State Key Laboratory of Natural Medicines (SKLNMZZ202309)
- China Pharmaceutical University (2632023GR25, 3012300091)
- Natural Science Foundation of Jiangsu Province (BK20210428)
- Science Fund for Distinguished Young Scholars of Jiangsu Province (7032300014-001)
- National Natural Science Foundation of China (82002971, 82104232, 82330119)
- Jiangsu Provincial Outstanding Postdoctoral Program (1412300102)
This publication has 46 references indexed in Scilit:
- Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinibCancer Communications, 2023
- Heterogeneity of cGMP signalling in tumour cells and the tumour microenvironment: Challenges and chances for cancer pharmacology and therapeuticsPharmacology & Therapeutics, 2023
- Getting to HBV cure: The promising paths forwardHepatology, 2022
- B3GAT3-related linkeropathy and an in-frame homozygous deletion in an adult patientEuropean Journal of Medical Genetics, 2021
- Biomimetic sulfated glycosaminoglycans maintain differentiation markers of breast epithelial cells and preferentially inhibit proliferation of cancer cellsActa Biomaterialia, 2021
- Lumican, pro-tumorigenic or anti-tumorigenic: A conundrumClinica Chimica Acta, 2021
- Goals and targets for personalized therapy for HCCHepatology International, 2019
- Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver DiseasesHepatology, 2018
- Glycosaminoglycans and glycolipids as potential biomarkers in lung cancerGlycoconjugate Journal, 2017
- Skeletal dysplasia in a consanguineous clan from the island of Nias/Indonesia is caused by a novel mutation in B3GAT3Human Genetics, 2015